A vaccine developed by US-based Pfizer and Germany's BioNTech has shown 90% efficacy in trials, but pharma giant says the number may vary with further trials.
Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing & development capacity in its home market.
Pfizer and BioNTech announced Monday that their vaccine candidate prevented over 90% of Covid-19 cases in an early look at results from their 44,000-person clinical trial.
With effectiveness for first vaccines previously expected to be in range of 60% to 70%, more than 90% for Pfizer’s Covid vaccine is seen as extraordinary.
Pfizer and BioNTech on track to potentially be the first to show the efficacy of a Covid-19 vaccine, in an environment of intense scrutiny over every possible complication.
A little patience would help deliver much more information and give other vaccine hopefuls, apart from the front-runners, a chance to prove their worth as well.
Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.
Disenfranchisement by institutional fiat is profoundly undemocratic. The effect of the ECI's new documentary process in Bihar will tilt the scales in favour of the BJP.
Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.
India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.
Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.
COMMENTS